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1 
RESUME 
 
 
The purpose of our work was to study the indicators of systemic inflammation in 
patients with chronic obstructive pulmonary disease (COPD) with anemia of chronic disease 
(AHD). 
 
Materials and methods of research. The study included 144 COPD patients (1 group) 
without anemia (hemoglobin> 120 g/l for women and> 130 g/l for men), and 33 patients (2 
group) with COPD and ACD (hemoglobin <120 g/l for women and <130 g/l for men, soluble 
transferrin receptors (sTFR) – 8.7 - 28.1 nmol/l). The control group included 62 practically 
healthy people. All patients were evaluated for the content of ferritin, C-reactive protein (C-
RP) and hepcidin. Statistical processing of the results was performed by using the SPSS-21 
program. 
 
Results. Patients with COPD and ACD have a significantly higher ferritin level (p 
<0.001) compared to COPD patients without anemia and patients in the control group. The 
content of C-RP and hepcidin in patients with COPD and ACD is also significantly (p 
<0.001) higher compared to patients without anemia and patients in the control group. 
 
Conclusion. Determination of the content of ferritin, C-RP and hepcidin in patients 
with COPD may allow adequate treatment for this group of patients. 
 
Key words: chronic obstructive pulmonary disease, inflammation, anemia of chronic 
disease, C-reactive protein, hepcidin 
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Introduction. Over the past century, new data appeared on the pathogenetic 
mechanisms of the development and course of COPD, as well as other clinical and laboratory 
manifestations, which previously seemed to be not related to the pulmonary pathology present 
in a patient. The development of clinical and fundamental medicine made it possible to 
distinguish various sets of symptoms (clinical and laboratory), which initially were hardly 
associated with the underlying disease, and which were rather interpreted as comorbidity. 
However, as the studies on COPD increased, the pathogenetic relationships between COPD 
and some clinical and laboratory syndromes became more clear and obvious. In this regard, 
most extrapulmonary manifestations are now interpreted as systemic effects of COPD [1]. 
The data obtained were eventually reflected in 2018 Global Strategy for the Diagnosis, 
Management, and Prevention of COPD [2]. It contains an indication of the systemic nature of 
this broncho-pulmonary pathology: “Morbidity from COPD may be affected by other 
concomitant chronic conditions (e.g., cardiovascular disease, musculoskeletal impairment, 
diabetes mellitus) related to COPD. These chronic conditions may significantly impair 
patient’s health status, in addition to interfering with COPD management.” The above is 
confirmed by the characteristics of COPD systemic manifestations: “Inflammatory mediators 
in the circulation may contribute to skeletal muscle wasting and cachexia, and may initiate or 
worsen comorbidities such as ischemic heart disease, heart failure, osteoporosis, normocytic 
anemia, diabetes, depression and metabolic syndrome.” 
 
Recent epidemiological studies show that 17–24% of patients with COPD have anemia 
and only 6–10% – have polycythemia [3, 4, 5]. The pathogenesis of anemia in patients with 
COPD is extremely complex and poorly understood. It has been established that hepcidin plays 
the role of a universal humoral regulator of iron (Fe) metabolism. It is proved that under the 
influence of pro-inflammatory cytokines, namely IL-6, IL-8, TNF-α, as well as acute phase 
proteins (C-reactive protein (C-RP), fibrinogen), hepcidin is overproduced by the liver 
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and blocks the receptors of ferroportin, a transmembrane protein that mediates iron release 
from cells (enterocytes, macrophages, hepatocytes) [6]. Hepcidin enhances iron redistribution 
from the bone marrow to macrophages and thus leads to impaired iron metabolism via 
increased iron accumulation in the cells of the macrophage system and impaired utilization of 
iron by erythroid cells for hemoglobin formation (iron-redistributing mechanism of anemia). 
At the same time, under the influence of cytokines, proliferation of erythroid precursor cells 
gets impaired and the erythrocyte life time shortens, which is probably associated with 
increased activity of the reticuloendothelial system and increased phagocytosis, as well as 
decreased expression of erythropoietin receptors [7]. In clinical studies, IL-10 proved to lead 
to anemia and increased ferritin content, reducing the availability of iron for red blood cell 
precursors [8]. IL-1β increased ferritin synthesis without increasing transcription or 
transcription receptor that is not associated with new iron intake. As a result, the authors 
suggested that IL-1β can lead to creation of direct intracellular iron repository, which cannot 
be used for hemoglobin synthesis [9]. 
 
Taking into account that studies of anemia of chronic disorder or, as it is also referred to, 
anemia of chronic disease (ACD) in patients with COPD are fragmentary, but most authors 
underline the key role of the chronic inflammatory process in the development of the anemia, 
further study of systemic inflammation markers is relevant in this category of patients. 
 
Objective. The objective of our work was to study the levels of systemic 
inflammation markers in patients with COPD, depending on the presence or absence of ACD. 
 
Materials and methods. We examined 202 patients with COPD, of which 144 
patients had no anemia, 33 patients had ACD, 12 – had erythrocytosis, and 13 – had iron 
deficiency anemia (IDA). COPD was diagnosed according to the recommendations of GOLD 
2014–2019, the diagnosis of anemia was made according to the recommendations of WHO: 
 
Hb <120 g/L for women and <130 g/L for men, ACD was diagnosed at the level of soluble 
 
4 
transferrin receptors (sTfR) 8.7–28.1 nmol/L, IDA was diagnosed at sTfR ˃28.1 nmol/L. For 
further analysis of systemic inflammation markers in patients with COPD and ACD, we 
formed two groups: Group I included 144 patients without anemia, Group II consisted of 33 
COPD patients with ACD. Patients were enrolled in the study after informed consent was 
obtained in accordance with the Helsinki Declaration of the World Medical Association on 
the Ethical Principles of Scientific and Medical Research. The study was approved by the 
Bioethics Committee for experimental and clinical studies at Sumy State University Medical 
Institute (protocol No. 2/1 of February 14, 2017). Inclusion criteria were: age 40 years and 
older, diagnosis of COPD. Exclusion criteria were: severe comorbid conditions (pulmonary 
tuberculosis, oncopathology, alcohol and/or drug abuse, AIDS, stage II or III heart failure, as 
well as decompensated hepatic or renal failure), known source of bleeding (complications of 
peptic ulcer, chronic ulcerative colitis, chronic hemorrhoids, etc.), previously diagnosed true 
anemias (megaloblastic, aplastic, hemolytic), use of ACE inhibitors, pregnancy or lactation, 
chronic administration of systemic GCs. The control group consisted of 62 apparently healthy 
individuals. Ferritin content was measured by latex-enhanced immunoturbidimetric assay 
using Roche reagent kits (Germany) on a Cobas c311 automatic analyzer (Japan). Serum CRP 
level was measured by the immunoturbidimetric assay using the Dialab kit (Austria) 
according to the manufacturer's guidelines. Serum hepcidin level was measured by solid-
phase enzyme immunoassay (ELISA) on Labsystems automated immunoassay analyzer, 
Multiscan MS (Finland) using Peninsula Laboratories International kit, Cat. No. S-1337, 
Hepcidin-25 (human) (USA) according to the manufacturer's guidelines. Statistical data were 
processed using SPSS-21 program. 
 
Results and discussion. 
 
The results of the analysis of inflammation markers content, namely ferritin, CRP, and 
hepcidin, are presented in Table 1. 
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Table 1 
 
The content of ferritin, C-reactive protein, and hepcidin in patients with chronic obstructive 
 
pulmonary disease, depending on anemia status 
 
 
    Group    
Parameter 
       
 1,  2,   Control group 
   Р1  Р2 Р3  
  n = 144  n = 33   n = 62 
        
Ferritin, 
m 259.04±0.81 0.001 475.8±2.23 0.954 0.001 262.02±3.38 
       
mcg/L 
       
 106.02±1.21 0.001 203.5±3.5 1.0 0.001 104.99±1.51   
 f       
        
CRP, mg/dL  1.56±0.2 0.001 2.97±0.5 0.001 0.001 0.476±0.14 
       
Hepcidin, ng/mL 21.4±0.12 0.001 32.07±0.36 0.001 0.001 13.62±2.29 
        
 
 
Notes: 
 
1. Р1 – statistical significance between Group I and Group II; 
 
2. Р2 – statistical significance between Group I and the control group; 
 
3. Р3 – statistical significance between Group II and the control group. 
 
 
 
 
It was found that patients with COPD and ACD had a higher level of ferritin compared 
with patients without anemia. Higher ferritin content can indicate a high level of iron pool and 
excludes iron deficiency, as the cause of this anemia. On the other hand, ferritin is an acute 
phase protein; therefore, its high content may be attributed to an active inflammatory process 
 
[10]. Along with high content of ferritin, high levels of CRP were observed in patients with 
COPD and ACD, which may also indicate the leading role of the inflammatory process as a 
 
cause of ACD in patients with COPD. Our analysis of the content of hepcidin, a protein that is 
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the main regulator of iron content, also showed a higher level of it in patients with COPD and 
ACD compared with patients without anemia, which may indicate a connection between the 
development of anemia and increased concentration of hepcidin. In order to determine, 
whether there is an association between hemoglobin level and inflammatory markers 
concentration, we carried out a correlation analysis between these parameters. A significant 
negative correlation was found between hemoglobin and hepcidin (r = -0.794; p <0.001), 
between hemoglobin and ferritin (r = -0.177; p = 0.001), between hemoglobin and CRP (r = - 
0.744; p <0.001), which may indicate an association between the levels of inflammation 
markers and hemoglobin in patients with COPD. 
 
According to the results of our study, patients with COPD and ACD have significantly 
higher ferritin content compared with patients with COPD without anemia and patients in the 
control group, which is consistent with the results of an earlier study [11]. According to the 
data of this study, ferritin can be used in the complex differential diagnosis of iron deficiency 
anemia and ACD, since its levels are normal to elevated in patients with ACD and are 
significantly reduced in patients with iron deficiency anemia. It should be noted that ferritin is 
a marker of inflammation, and also performs the function of iron storage in a soluble form, 
which can explain its high content in patients with COPD and ACD. These data add to the 
results of other authors who found that IL-10 and IL-1β as pro-inflammatory cytokines 
contribute to an increase in ferritin content [7, 12]. According to literature sources, patients 
with COPD and anemia show a high level of CRP and IL-6 [13]. Similar results were 
observed in our study, that is, the content of CRP and hepcidin in the studied patients with 
COPD and ACD was also significantly higher compared with patients without anemia and the 
control group. A higher content of CRP in patients with ACD compared with patients without 
anemia may indicate an active and pronounced inflammatory process in the group of patients 
with COPD and ACD. Our results are consistent with the results of German researchers who 
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found that in patients with ACD, increased serum prohepcidine level is associated with 
increased storage of ferritin in monocytes [9]. Nemeth E. et al. found that hepcidin mRNA 
expression can get increased simultaneously with an increase in serum ferritin and IL-6 levels 
[14], and the results of our study demonstrate a simultaneous increase in serum ferritin, CRP, 
and hepcidin in patients with COPD, whereas patients with COPD and ACD have 
significantly higher concentrations of the presented markers of inflammation. Recent 
experimental study by Kemna E. et al. presented evaluation and demonstrated the dynamic 
pattern for inflammation markers and, as a result, changes in serum iron content under the 
influence of lipopolysaccharides. It was found that administration of lipopolysaccharides 
increases IL-6 level after 3 hours, urine hepcidin level – after 6 hours, CRP level – after 12 
hours, and reduces serum iron level after 22 hours by 12 mmol/L [15]. Data on administration 
of IL-6 in patients with Hodgkin's lymphoma add to the information on the role of pro-
inflammatory cytokines and hepcidin in the development of ACD: a rapid increase in urine 
hepcidin was found with its further recovering within 24 hours. It is important to note that 2 
hours after the infusion, serum iron level decreased by 34%, and transferrin saturation 
decreased by 33% [16]. The results of our study are consistent with those obtained in the 
study of Parveen S. et al. – the authors found a negative correlation between hemoglobin and 
CRP in patients with COPD [5]. Thus, we conducted a comprehensive study of systemic 
inflammation markers in patients with COPD, as well as of the correlation between 
inflammatory markers level and hemoglobin concentration in patients with COPD. 
 
Conclusions. 
 
Patients with COPD and ACD had significantly higher levels of ferritin, CRP, and 
hepcidin as compared to patients without anemia and the control group. 
 
The concentration of ferritin, CRP, and hepcidin negatively correlates with 
hemoglobin levels in patients with COPD. 
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